# Radionetics Oncology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/radionetics-oncology

- Industry: Pharmaceuticals
- Headquarters: Menlo Park, US
- Website: www.radionetics.com
- Total disclosed funding: $108M
- Latest round: Series A (Aug 1, 2023)
- Investors on record: 5

## About

Radionetics Oncology, Inc. is a US-based biotechnology firm dedicated to developing targeted small molecule radiopharmaceuticals aimed at transforming the treatment landscape for solid tumors.Founded in 2021 in Menlo Park, US, Radionetics Oncology specializes in precision oncology medications. The company was established by R Struthers, who has a notable background in the biotech sector. As of August 1, 2023, Radionetics raised USD 54.21 mn in Series A funding from GordonMD Global Investments and other investors, bringing the total funds raised to USD 54.21 mn with a current company valuation of USD 92.97 mn.Radionetics specializes in developing targeted small molecule radiopharmaceuticals, which utilize a precise methodology to deliver radiation directly to cancerous tumors while minimizing damage to healthy tissues. Their innovative pipeline includes treatments targeting G protein-coupled receptors (GPCRs), prevalent in various cancers, primarily serving oncology clinics and healthcare providers in the US and internationally.Radionetics operates a revenue model based on partnerships with major pharmaceutical companies, including a strategic agreement with Lilly, which featured a USD 140 mn upfront payment and an option for Lilly to acquire Radionetics for USD 1 bn. Their business model focuses on B2B engagements, allowing for the licensing of proprietary GPCR-targeting radiopharmaceuticals, supported by milestone payments and royalties from successful product commercialization.In August 2023, Radionetics raised USD 54.21 mn in Series A funding, which will be directed towards advancing their product pipeline and strategic expansions. The company is focused on launching new therapeutics targeting additional cancer types and plans to extend its market presence into Europe and Asia by 2025. This funding will facilitate the development and commercialization of their radioligand therapies, aiming to address significant unmet medical needs in oncology.

## Funding rounds

- Series A, Aug 1, 2023, $54M — GordonMD Global Investments
- Series A, Aug 1, 2023, $54M — Frazier Healthcare Partners, 5AM Ventures, DCVC, Crinetics Pharmaceuticals, Inc., GordonMD Global Investments

## Investors

- GordonMD Global Investments (https://capitalatlas.ai/funds/gordonmd-global-investments) — Series A
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A
- DCVC (https://capitalatlas.ai/funds/dcvc) — Series A
- Crinetics Pharmaceuticals, Inc. — Series A